A class action claims Florida-based BPI Sports' bodybuilding and dietary supplements "contain a dangerous amphetamine-like ingredient that poses a serious health risk and has potentially life-threatening side effects."
BPI's best selling products include '1.M.R' powder and tablets, 'RoxyLean ECA' and 'Rx6' (collectively, the 'products.') These products are purported dietary supplements which are marketed for use as bodybuilding and weight loss supplements. 1.M.R is marketed as a pre-workout bodybuilding supplement. RoxyLean and Rx6 are marketed as 'fat burning' weight loss supplements.
"DMAA was patented by Eli Lilly & Company in 1944 and later marketed, beginning in 1971, under the trademark 'Forthane' for use as a nasal decongestant and as a treatment for hypertrophied or hyperplasic oral tissues. DMAA is a vasoconstrictor and central nervous system stimulant which is on the World Anti-Doping Agency ('WADA') and Major League Baseball ('MLB') lists of banned substances. The sale of DMAA is totally prohibited in Canada and New Zealand. Recently, DMAA has gained popularity with young people as a designer drug used in 'party pills.'
"BPI failed to inform consumers that DMAA is a dangerous central nervous system stimulant which is banned by WADA, MLB, Canada and New Zealand, and that using the products can cause consumers to test positive for an illegal substance and/or amphetamine use., says the lawsuit.
Here are the defendants: BPI Sports LLC, BPI Sports Holdings Inc., Brian Pharma II LLC, and BPI principals Derek Ettinger and James Grage.
Tuesday, February 7, 2012
Savannah DMAA Supplement Lawsuit News 2/6/2012
The Department of Defense temporary halted the sales of products containing 1,3-dimethylamylamine (DMAA) within military facilities after recent reports showed two soldier deaths and additional adverse health effects in other service members may be related to use of the dietary supplements.
The Department of Defense's moratorium will remain in effect pending further review of relevant scientific evidence and reported events.
The Assistant Secretary of Defense for Health Affairs Jonathan Woodson asked the surgeons general of the military services to conduct a review of available scientific evidence and adverse event reports (AERs) to better understand any potential relationship between DMAA and these events.
DMAA has been cited in a class action lawsuit claims bodybuilding and supplements from Florida-based BPI Sports contained undisclosed 1,3-dimethylamylamine (DMAA), an amphetamine-like ingredient that poses a serious health risk and has potentially life-threatening side effects, according to the suit.
The plaintiffs seek restitution and class damages for consumer law violations, unfair competition, false and misleading advertising, breach of express warranty and breach of implied warranty.
DMAA is banned by several athletic organizations, including the World Anti-Doping Agency and Major League Baseball. It is illegal to sell in many countries, including Canada and New Zealand. The lawsuit says the ingredient is supposedly derived from the oil of the geranium plant. DMAA, also known as Methylhexanamine and Geranainine, is a vasoconstrictor and central nervous system stimulant.
http://www.naturalproductsinsider.com/news/2011/11/lawsuit-claims-supplement-contained-dmaa.aspx
The Department of Defense's moratorium will remain in effect pending further review of relevant scientific evidence and reported events.
The Assistant Secretary of Defense for Health Affairs Jonathan Woodson asked the surgeons general of the military services to conduct a review of available scientific evidence and adverse event reports (AERs) to better understand any potential relationship between DMAA and these events.
DMAA has been cited in a class action lawsuit claims bodybuilding and supplements from Florida-based BPI Sports contained undisclosed 1,3-dimethylamylamine (DMAA), an amphetamine-like ingredient that poses a serious health risk and has potentially life-threatening side effects, according to the suit.
The plaintiffs seek restitution and class damages for consumer law violations, unfair competition, false and misleading advertising, breach of express warranty and breach of implied warranty.
DMAA is banned by several athletic organizations, including the World Anti-Doping Agency and Major League Baseball. It is illegal to sell in many countries, including Canada and New Zealand. The lawsuit says the ingredient is supposedly derived from the oil of the geranium plant. DMAA, also known as Methylhexanamine and Geranainine, is a vasoconstrictor and central nervous system stimulant.
http://www.naturalproductsinsider.com/news/2011/11/lawsuit-claims-supplement-contained-dmaa.aspx
Tuesday, January 24, 2012
.FDA Issues Warning About Lymphoma Drug Brentuximab
The US Food and Drug Administration (FDA) has issued a warning to healthcare professionals about the lymphoma drug brentuximab (Adcetris, Seattle Genetics).
Two new cases of progressive multifocal leukoencephalopathy (PML), which is a rare but serious brain infection, have been reported. Because of the seriousness of PML, which can result in death, a new boxed warning highlighting this risk has been added to the drug label, according to the FDA.
In addition, a contraindication was added, warning against the use of brentuximab with the cancer drug bleomycin because of the increased risk for pulmonary toxicity.
Brentuximab was approved by the FDA in August 2011 for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. At the time of approval, 1 case of PML was described in the warnings and precautions section of the label. So there are now 3 cases associated with the drug.
The signs and symptoms of PML can develop over the course of several weeks or months. They can include changes in mood or usual behavior; confusion; thinking problems; loss of memory; changes in vision, speech, or walking; and decreased strength or weakness on one side of the body, the FDA says.
Healthcare professionals should suspend brentuximab dosing if PML is suspected, and discontinue the drug therapy if a diagnosis of PML is confirmed, according to the FDA.
Brentuximab generated much excitement among experts when study results were presented at the American Society of Hematology annual meeting in 2010. Some of the responses seen in refractory lymphoma were described as "amazing." The new drug is the first to be approved by the FDA for Hodgkin's lymphoma in more than 30 years, the company said.
Sunday, January 8, 2012
Lawyers: Why I follow (some of) you on Twitter
 |
| Image via CrunchBase |
On Twitter for one of our accounts we have taken a deliberate approach to following certain types of attorneys. We have compiled a list of lawyers by state and by specialty. For specialties, I follow attorneys in these areas: Criminal law, family law, estates, transactional, and immigration. I don't spend much time seeking out or searching for IP lawyers (unless they are interesting) or construction.
Why do I follow in those areas at all? Because our office now is actively involved in litigation in multiple Multi District Litigation matters involving unsafe/recalled products across the country. We are not limited to the south in our practice, and of the many people we represent, on average (we keep records) we have current clients asking about 30-50 times a month law questions other areas of law we don't practice, as well as in states we are not licensed in.
So, if you wonder why one of us decides to follow you now some of you know.
Subscribe to:
Posts (Atom)